Novavax COVID-19 trial highlights differences between U.K., U.S. approaches

Novavax’s just-launched U.K. trial of its COVID-19 vaccine brings into focus the different approaches that Operation Warp Speed in the U.S. and the U.K. Vaccine Taskforce are taking to rapidly determine safety and efficacy.

The U.K. trial, which is being conducted in partnership with the task force, has two primary endpoints, prevention of symptomatic COVID-19 and prevention of moderate or severe COVID-19. This is in contrast with U.S. Phase III trials which have a single primary endpoint, prevention of symptomatic COVID-19. ...